NDRA · ENDRA Life Sciences Inc.

ENDRA Life Sciences reported a challenging Q1 2026 with operating losses widening to -$2.2 million from -$1.5 million in the prior year, driven by continued investment in the pre-commercial TAEUS technology platform. The company has not yet completed commercialization of any TAEUS applications, maintaining focus on development for the liver application targeting NAFLD while pursuing FDA approval. This phase demands sustained R&D spending, contributing to the 47.9% year-over-year operating loss expansion as resources are directed toward product improvements and regulatory strategy rather than revenue-generating activities.

Cash flow dynamics improved modestly, with net cash used in operating activities at -$1.1 million versus -$1.3 million last year, leading to free cash flow of -$1.1 million after $17 thousand in capital expenditures—unchanged from prior year. These trends align with proactive cost reduction measures implemented during the quarter, including headcount reductions and a shift from clinical to development activities. This restructuring extends the operating runway amid financial and operating challenges, conserving resources while prioritizing high-impact areas like TAEUS liver regulatory progress.

Liquidity remains a critical focus, with the company experiencing near-term pressures and long-term uncertainties tied to commercialization timelines. Public company costs persist, encompassing Nasdaq compliance, SEC filings, D&O insurance, legal, accounting, and investor relations expenses. Management's go-to-market vision emphasizes a subscription-based model for recurring revenue in targeted markets, supplemented by traditional equipment sales and services, though execution awaits TAEUS milestones. Forward R&D will continue as the company advances toward FDA clearance, balancing innovation with capital discipline.